293 related articles for article (PubMed ID: 31699827)
21. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
[TBL] [Abstract][Full Text] [Related]
22. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
[TBL] [Abstract][Full Text] [Related]
23. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
24. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD; Gregory GP; Hargreaves D; Hendricks JA; Johannes JW; Johnstone RW; Kazmirski SL; Kettle JG; Lamb ML; Matulis SM; Nooka AK; Packer MJ; Peng B; Rawlins PB; Robbins DW; Schuller AG; Su N; Yang W; Ye Q; Zheng X; Secrist JP; Clark EA; Wilson DM; Fawell SE; Hird AW
Nat Commun; 2018 Dec; 9(1):5341. PubMed ID: 30559424
[TBL] [Abstract][Full Text] [Related]
25. Ligand- and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia.
Zhang H; Huang J; Chen R; Cai H; Chen Y; He S; Xu J; Zhang J; Wang L
Bioorg Med Chem; 2022 Oct; 72():116994. PubMed ID: 36087428
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
[TBL] [Abstract][Full Text] [Related]
27. Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers.
Freeman DB; Hopkins TD; Mikochik PJ; Vacca JP; Gao H; Naylor-Olsen A; Rudra S; Li H; Pop MS; Villagomez RA; Lee C; Li H; Zhou M; Saffran DC; Rioux N; Hood TR; Day MAL; McKeown MR; Lin CY; Bischofberger N; Trotter BW
J Med Chem; 2023 Dec; 66(23):15629-15647. PubMed ID: 37967851
[TBL] [Abstract][Full Text] [Related]
28. BIRC6 mediates imatinib resistance independently of Mcl-1.
Okumu DO; East MP; Levine M; Herring LE; Zhang R; Gilbert TSK; Litchfield DW; Zhang Y; Graves LM
PLoS One; 2017; 12(5):e0177871. PubMed ID: 28520795
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma.
Zhao X; Bodo J; Chen R; Durkin L; Souers AJ; Phillips DC; Hsi ED
EJHaem; 2020 Jul; 1(1):161-169. PubMed ID: 35847704
[TBL] [Abstract][Full Text] [Related]
30. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
31. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
[TBL] [Abstract][Full Text] [Related]
32. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Lee DJ; Zeidner JF
Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
[No Abstract] [Full Text] [Related]
33. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
[TBL] [Abstract][Full Text] [Related]
34. MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer.
Zhang H; Huang C; Gordon J; Yu S; Morton G; Childers W; Abou-Gharbia M; Zhang Y; Jelinek J; Issa JJ
Clin Epigenetics; 2024 Jan; 16(1):3. PubMed ID: 38172923
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
36. Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity Evaluation.
Zhong Y; Xu J; Zhou R; Tang L; Ding S; Ren Z; Song N; Hu B; Yang H; Sun Y; Cheng M; Li J; Liu Y
J Med Chem; 2024 Mar; 67(6):4739-4756. PubMed ID: 38488882
[TBL] [Abstract][Full Text] [Related]
37. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
38. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.
Liu X; Shi S; Lam F; Pepper C; Fischer PM; Wang S
Int J Cancer; 2012 Mar; 130(5):1216-26. PubMed ID: 21484792
[TBL] [Abstract][Full Text] [Related]
39. CDK9 inhibitors in multiple myeloma: a review of progress and perspectives.
Borowczak J; Szczerbowski K; Ahmadi N; Szylberg Ł
Med Oncol; 2022 Jan; 39(4):39. PubMed ID: 35092513
[TBL] [Abstract][Full Text] [Related]
40. Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.
Jorda R; Navrátilová J; Hušková Z; Schütznerová E; Cankař P; Strnad M; Kryštof V
Chem Biol Drug Des; 2014 Oct; 84(4):402-8. PubMed ID: 24803299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
